Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Praxis Precision Medicines's Ulixacaltamide?
Ulixacaltamide is a small molecule commercialized by Praxis Precision Medicines, with a leading Phase III program in Essential Tremor. According...